Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma

NCT00635323 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
73
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer